1 Result: Acelyrin
Acelyrin (SLRN), CRISPR Therapeutics (CRSP), Elevation Oncology (ELEV), STERIS (STE), Teleflex (TFX): Analyst Coverage and Potential Upside Revealed
May 30th, 2023
Acelyrin, Inc. (Nasdaq: SLRN), a pharmaceutical company dedicated to developing innovative therapies, caught the attention of Jefferies, which initiated coverage on the stock with a Buy rating and a price target of $31. Despite $SLRN closing. Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
Micron Technology, Jabil, and Birkenstock Earnings Preview: What to Expect
December 15th, 2024Upcoming Earnings: Synopsys, AeroVironment, and nCino in Focus
December 01st, 2024Countdown to Earnings: Salesforce, Marvell Technology, and Okta Take the Stage
December 01st, 2024Fluence Energy, Agilent Technologies, and Woodward Earnings On Deck: A Preview
November 24th, 2024Earnings Preview: Walt Disney, Applied Materials, and Celcuity Take Center Stage
November 11th, 2024
Member Login